The Cooper Companies, Inc. (NASDAQ: COO) — A Wide-Moat Lens Franchise Trapped Inside a Roll-Up, at Its Cheapest Multiple in a Decade

Independent equity research. Report date: 2026-07-04. Fiscal year ends October 31. All share/price figures reflect the 4-for-1 stock split effective 2024.

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — it is not investment advice. The analysis that follows is deliberately position-free and carries no price target anywhere except inside this block.

Verdict: HOLD / accumulate-on-weakness — a quality-compounder-at-a-price, not-a-short and not-a-chase. Fair-value zone ~$70–85 (~15–17x a ~$4.62 adjusted EPS, ~14–16x EV/EBITDA, ~5% normalizing FCF yield); genuine value below ~$65 (toward the May panic low of ~$59); no case to chase above ~$90 until Asia-Pac stabilizes and the separation is on the table. At ~$74 you are paying ~16x forward adjusted earnings and ~15x EV/EBITDA for The Cooper Companies — the cheapest it has been on price-to-sales (≈5th percentile of its own decade) and price-to-book (≈7th percentile) in living memory, for a business whose crown jewel, CooperVision, is a genuine member of a four-firm global contact-lens oligopoly earning a 26.6% segment operating margin with structural myopia-driven growth. The headline GAAP P/E of ~40–60x is a mirage: it divides the price by an EPS that ~$200M/yr of acquisition-intangible amortization has crushed to $1.87, when the business actually earns ~$4.62 of cash EPS and threw off enough cash for management to raise its FY26 free-cash-flow guide to ~$650M and reaffirm $2.2B of cumulative FCF across FY26–28 even as it cut the revenue outlook.

Here is why it is only a HOLD and not a table-pound. On reported numbers COO earns a ~4–5% return on invested capital — below its cost of capital — because ~$3.85B of goodwill and a matching pile of intangibles from the CooperSurgical roll-up sit on top of a business that generates ~$680M of GAAP operating income. That is the ZBH problem in miniature: a franchise-quality operating asset (CooperVision alone earns ~27% operating margins on ~$2.7B of sales) diluted by a lower-return, amortization-heavy women’s-health roll-up (CooperSurgical: 3.2% GAAP operating margin after $178M of amortization, ~16% on a cash/EBITA basis). The framing is de-rated quality / a slow falling knife now stabilizing, with a special-situation kicker: the tape reads COO as a low-beta (0.72), negative-momentum, abandoned name — five years of negative Sharpe, ~35% below its 2021 high, a −34.9% relative-strength drawdown from peak — the empirical opposite of a crowded trade. But two things the bears are under-weighting: (1) the capex super-cycle is ending — COO spent 9–11% of sales for years building silicone-hydrogel lens capacity, and as that normalizes, FCF inflects hard (FY23 $215M → FY25 $434M → FY26 ~$650M → ~$730M+ run-rate); and (2) the strategic review that could separate CooperSurgical is the literal cure for the ROIC drag — a clean CooperVision pure-play would be a ~27%-margin, high-growth, high-ROIC consumable that the market pays 20–25x EBITDA for (cf. Alcon), not the ~15x the blended entity fetches today. You are being paid to wait via a cheap multiple, a coming cash flood, and free optionality on a value-unlocking split — and you are not waiting alone: activist JANA Partners is involved, the board has been refreshed, and management’s base case is an outright separation, while a broad cluster of insiders (CEO White bought ~$1.5M of stock) sold the 2024 highs and bought the 2025 selloff. What holds me back from more: growth has genuinely decelerated to the low end of its historical 4–6% band, the Asia-Pac (Japan/China) consumer softness is real and un-fixed, MiSight’s myopia-control lead is being nibbled by spectacle-lens rivals, and reported FY26 free cash flow will be dented by ~$272M of embryo-recall settlement cash (the ~$650M guide is stated ex-litigation) — so the cash inflection is underlying, not yet fully visible on the FY26 print.

Conviction: medium. Catchy tag: “The lens is the moat; the surgery is the anchor — and management is finally reaching for the chain.” The single piece of evidence that would flip me decisively bullish: a formal move to separate CooperSurgical, or two clean quarters of Asia-Pac stabilization with the FCF inflection landing on plan — either re-rates the sum toward the parts (~$90+). The single piece that would flip me bearish: CooperVision organic growth breaking below ~3% on accelerating myopia-control share loss to spectacles plus spreading Asia-Pac weakness, with the FCF ramp slipping — that turns “cheap quality compounder” into “structurally maturing roll-up,” fair value back toward the high-$50s.

📈 Stock Price Action — Five-Year Event Map

Factual price history, split-adjusted; the price move is FACT, the attributed cause is INTERPRETATION. No recommendation or price target here — that lives in Claude’s Take above.

Over five years COO has round-tripped and then some: from a pandemic-era high near ~$114 (Sept 2021), down to ~$68 (Oct 2022), back to ~$105 (Oct 2024), then a fresh leg down to a five-year low of $58.98 (11 May 2026), recovering to $74.20 (2 July 2026). The stock sits ~35% below its five-year high, in a 52-week range of roughly $59–$84, at a decade-trough valuation. This is not one crash but a multi-year de-rating of a decelerating, capex-heavy compounder, punctuated by a 2026 macro-plus-Asia-Pac air pocket.

Cycle narrative. (1) COO peaked in 2021 with the rest of long-duration medtech as pandemic-recovery volumes and a hot myopia narrative pushed the multiple toward ~27x EV/EBITDA. (2) 2022’s rate shock compressed that multiple by a third even as revenue grew — the classic duration de-rate — with the debt-funded Generate Life Sciences acquisition adding balance-sheet weight. (3) 2023 saw a sharp recovery on genuine lens share gains before fading. (4) 2024 was the last hurrah: a run to ~$105 on record CooperVision growth and the confidence-signal 4-for-1 split. (5) Through 2025 the stock de-rated a third time as organic growth slowed toward the low end of the 4–6% band and Asia-Pac cracks appeared. (6) In spring 2026 a broad rate-driven risk-off (the “Nasdaq-100 plunges 3%” tape) collided with company-specific Japan/China consumer softness to mark a $58.98 low on 11 May; the 4 June Q2 print — an EPS beat, a raised FCF guide, but a cut revenue outlook — produced an initial pop, a wave of price-target cuts ($66–$92), and a net recovery to ~$74. Each move traces to a research-log entry and is cross-referenced against the earnings prints, 8-K events, and the news feed.

1. Executive Summary

The Cooper Companies is a ~$4.1B-revenue medical-device business built from two very different franchises. CooperVision (67% of sales, ~$2.74B) is one of four global contact-lens majors — alongside Johnson & Johnson (Acuvue), Alcon, and Bausch + Lomb — that together control the overwhelming majority of a structurally growing ~$10–11B market. It is a razor/razor-blade consumable with 65%+ gross margins, a 26.6% segment operating margin, a #1 position in EMEA, a leading daily silicone-hydrogel portfolio (MyDay, clariti, Biofinity), and the only FDA-approved contact lens for pediatric myopia control (MiSight) — the industry’s most important structural growth vector as childhood myopia reaches epidemic levels. CooperSurgical (33%, ~$1.35B) is a fertility and women’s-health roll-up assembled through ~$3B+ of acquisitions (Paragard, Cook reproductive, Generate Life Sciences); it owns the only non-hormonal copper IUD sold in the US (Paragard) and a broad fertility-consumables/genomics platform in a structurally growing IVF market, but at materially lower returns and with $178M/yr of acquisition-intangible amortization.

That amortization is the analytical key to the whole story. It crushes GAAP EPS to $1.87 (vs ~$4.62 of adjusted/cash EPS) and drags blended GAAP ROIC to ~4–5% — below the cost of capital — making COO screen as expensive (GAAP P/E ~40–60x) when it is in fact cheap: ~15x EV/EBITDA, ~4x EV/sales, ~16x forward adjusted earnings — the lowest multiples in a decade (price-to-sales and price-to-book both near the bottom decile of their own history). Three things are converging: (1) a free-cash-flow inflection as a multi-year lens-capacity capex super-cycle (9–11% of sales) normalizes — FCF has gone $215M (FY23) → $434M (FY25) → a guided ~$650M (FY26), with management reaffirming $2.2B cumulative FCF FY26–28; (2) an activist-backed (JANA Partners) strategic review that could separate CooperSurgical, with proceeds earmarked for buybacks — directly unlocking the CooperVision pure-play the roll-up currently masks, and corroborated by a broad insider-buying cluster (the CEO bought ~$1.5M into the 2025 selloff); and (3) a decade-low valuation on a low-beta, negative-momentum, abandoned tape.

Against that: organic growth has decelerated to the low end of its 4–6% historical band; Asia-Pac (especially Japan and China) consumer softness forced a FY26 revenue-guide cut; MiSight’s myopia-control franchise faces competition from spectacle-lens rivals (HOYA, EssilorLuxottica); and the reported returns will remain optically poor until the CooperSurgical goodwill/amortization question is resolved. This memo takes no position and sets no target; it lays out the embedded expectations, the sum-of-the-parts, and the falsification tests for each side. The judgment is reserved for Claude’s Take above.

2. Business Overview

The Cooper Companies (founded 1958, headquartered in San Ramon, California) reports two operating segments.

CooperVision (FY2025 net sales $2,743.8M, 67% of total). A pure contact-lens business. Revenue splits into toric & multifocal lenses ($1,351.3M) — the higher-value, harder-to-manufacture “complex” categories that correct astigmatism (toric) and presbyopia (multifocal) — and sphere & other ($1,392.5M), the base near/far-sighted correction plus MiSight myopia-control lenses. The economic model is a classic consumable annuity: lenses are single-use (dailies) or short-cycle (bi-weekly/monthly) and must be repurchased continuously, so ~virtually all revenue is recurring. COO manufactures molded lenses at scale in Costa Rica, Hungary, Puerto Rico, the UK and the US. Growth is driven by (a) the mix shift from reusable to daily disposables, (b) the shift within dailies from hydrogel to premium silicone hydrogel (higher oxygen permeability, higher ASP), © toric/multifocal penetration, and (d) MiSight, the myopia-control franchise. Segment GAAP operating income was ~$729.6M — a 26.6% operating margin on only $21.0M of amortization.

CooperSurgical (FY2025 net sales $1,348.6M, 33%). Family and women’s health, split into office & surgical products ($824.0M) — OB/GYN surgical devices, the Paragard copper IUD, fetal/maternal devices, LEET/ablation systems — and fertility ($524.6M) — IVF consumables and equipment, donor-gamete services, genomics/genetic testing, and cryostorage (cord blood/tissue). This segment was assembled largely by acquisition; it carries the bulk of group amortization ($178.2M) and posted only ~$43.4M of GAAP operating income (3.2% margin), though on an EBITA/cash basis it earns closer to ~16%. Management notes CooperSurgical’s FCF-per-revenue-dollar actually exceeds CooperVision’s today because it carries less capex.

Customers span distributors, group purchasing organizations, eye-care and health-care professionals, corporate optical retailers, hospitals and fertility clinics. Roughly two-thirds of revenue is international, giving COO meaningful FX exposure (a swing factor in FY26 guidance). The business is modestly seasonal — fiscal Q1 (Nov–Jan) is the low quarter as patient traffic dips.

[Verdict — a high-quality consumable franchise (CooperVision) bolted to a decent-but-lower-return roll-up (CooperSurgical); the two are only loosely synergistic, which is precisely why a separation is under review.]

3. Industry Dynamics

COO operates in two structurally attractive but very different end markets.

Contact lenses — a rational four-player oligopoly. The global soft contact-lens market is ~$9.8B at the manufacturer level (2024), growing ~6–8%/yr, and is one of the more attractive consumer-medtech structures in existence: four firms — J&J Vision (Acuvue), Alcon, CooperVision, Bausch + Lomb — control ~95%+ of volume. Triangulated global soft-lens share sits roughly at J&J ~40–43% (#1), CooperVision ~28–30% (#2 globally), Alcon ~24%, B+L ~8–10%. CooperVision is #3 in the US but #1 in EMEA by both revenue and wearers, and #1 globally in the specialty fits (toric, multifocal, myopia). Crucially, this is a unit-growth + positive-mix industry, not a raw price-hike one: the value creation comes from patients trading up — reusable → daily disposable, hydrogel → silicone hydrogel (now ~70% of revenue), sphere → toric/multifocal — each step lifting revenue-per-wearer several-fold. Four disciplined incumbents play the pricing game cooperatively; there are no price wars. Silicone-hydrogel manufacturing is high-fixed-cost and demands enormous SKU/parameter breadth (thousands of power/base-curve/cylinder/axis combinations), which only the big four can economically supply — a formidable barrier to entry.

Myopia management — the crown-jewel growth vector. Childhood myopia has reached epidemic levels, especially in East Asia, and the myopia-control lens market is projected to grow from ~$1.64B (2025) to ~$4.0B (2034), a ~15.6% CAGR (~88% of it Asia-Pacific). MiSight 1 day is the only FDA-approved contact lens (2019) for slowing childhood myopia and won Japanese approval in 2025. The competitive complication: most myopia-control alternatives are spectacle lenses — HOYA MiYOSMART (>12M lenses sold, reimbursed in France from 2025), EssilorLuxottica Stellest, ZEISS — plus ortho-K and low-dose atropine. MiSight’s edge is its regulatory/clinical-evidence lead as the sole FDA-cleared soft contact lens, but it is not the only solution, and cheaper reimbursed spectacles are a genuine share threat management itself flagged as a “short-term negative.”

Fertility / IVF — a secular grower, consolidating. The IVF market is ~$28B (2025) heading to ~$46B (2034), ~5.7% CAGR, driven by delayed childbirth, ~1-in-6 global infertility incidence, and expanding insurance coverage (California’s SB 729 mandates large-group infertility coverage from January 2026 — a structural US demand expansion). CooperSurgical plays the “picks-and-shovels” lab-consumables niche (culture media, incubators, micromanipulation, cryostorage, PGT/genetics) rather than owning clinics, competing in a tight oligopoly with Vitrolife, Thermo Fisher/Irvine, Cook Medical, and the newly-consolidated Hamilton Thorne (taken private by Astorg, bolting on Cook’s IVF unit). Paragard — the only non-hormonal/copper IUD approved and sold in the US (bought from Teva in 2017 for ~$1.1B) — is a genuine regulatory mini-monopoly, but mature, flat-to-declining, and litigation-exposed (device-breakage suits); it is a cash annuity, not a growth asset.

[Verdict — structurally GOOD industries. The contact-lens oligopoly is one of the best structures in medtech (high barriers, disciplined pricing, secular mix-up, myopia optionality); fertility is a consolidating secular grower where COO holds a defensible consumables niche. Paragard is a durable but shrinking monopoly annuity. The regional caveat is Asia-Pac cyclicality.]

4. Competitive Position

CooperVision — a genuine moat: economies of scale + customer captivity (Greenwald’s strongest, most durable combination), plus the MiSight intangible. The scale advantage is specific and defensible: silicone-hydrogel production is high-fixed-cost and requires thousands of SKUs to serve the toric/multifocal/myopia specialty categories where COO is #1 — scale in the relevant niche, which is exactly where Greenwald says scale advantages bite hardest. Layered on top is customer captivity via the agency relationship: the buyer who chooses the lens is the eye-care practitioner who fits it; the patient is then captive to the fitter’s chosen brand (habit, comfort, and the search/re-fit cost of switching) and re-orders a frequent, automatic consumable. That captivity shows up cleanly in the financials — a ~66% gross margin and a 26.6% segment operating margin that would not survive absent the moat. MiSight adds an intangible/regulatory edge (sole FDA-approved myopia-control contact lens plus a multi-year pediatric dataset rivals cannot instantly replicate). Pressure-test: the moat is real at the premium/specialty/myopia level; the commodity sphere segment is more contestable, and online/private-label players (Hubble, 1-800 Contacts) plus market growth itself — the classic enemy of scale advantages — modestly erode low-end captivity. Net: a durable share-defense franchise, not a share-gain-forever machine.

CooperSurgical — a weaker, heterogeneous moat. Fertility consumables carry moderate switching costs (a validated embryology lab will not lightly re-validate its media/incubator protocols) and some bundling power (one-stop media + incubators + genetics + devices), but that moat is shared with Vitrolife and Thermo Fisher, not exclusive. Paragard is a pure regulatory monopoly — strong but narrow, mature, and litigation-clouded. The December-2023 embryo culture-media recall dented precisely the trust/switching-cost asset the fertility franchise rests on; “largely settled” limits but does not erase the reputational hit.

The reconciliation that matters. Consolidated GAAP ROIC of ~4–5% is not evidence of “no moat” — it is an accounting artifact of blending ~$3.85B of CooperSurgical roll-up goodwill against a high-return CooperVision consumable. The segment economics diverge sharply (26.6% vs 3.2% GAAP operating margin), which is the entire rationale for the strategic review. [Verdict — CooperVision has a durable, financially-visible competitive advantage; CooperSurgical has a narrower, shared, partly-regulatory one. This is a two-speed business masquerading as one mediocre-return company.]

5. Growth History and Forward Opportunities

History. Revenue compounded ~11% from FY2020–25 to $4.09B, but that growth was heavily acquired (the CooperSurgical fertility roll-up plus Paragard) — which is exactly why goodwill drags reported returns. The composition has since shifted toward higher-quality organic growth: Q2 FY26 delivered CooperVision +4% organic (Americas +7%, EMEA +6%, Asia-Pac −6%) and CooperSurgical +6% organic with fertility +10–13% organic, MiSight +24%, and Paragard flat (a beat). The through-line: today’s growth is more organic, more recurring, and more margin-accretive than the acquisition-led growth of the prior decade.

Forward drivers. (1) Global myopia rollout — MiSight and the newly-launched MyDay MiSight into Japan and Asia-Pac is the single largest optionality, in a market compounding ~15%; (2) MyDay daily silicone-hydrogel share gains and premium mix-up (double-digit growth); (3) fertility recovery aided by SB 729 and improving IVF cycle volumes; (4) the Paragard flat annuity; and (5) continued premium momentum in EMEA and the Americas.

The headwind. Asia-Pacific — the fastest-growing lens region and the ultimate myopia prize — is simultaneously the near-term drag: −6% in Q2 FY26 on legacy-product rationalization plus genuine consumer weakness in Japan and China, guided to decline again in Q3 before stabilizing toward market growth by Q4. That forced the FY26 revenue-guide cut. The bull reads this softness as cyclical (consumer, not structural share loss); the bear reads it as the leading edge of maturation. Management’s framing (“regional, not global; temporary”) is a hypothesis to be validated over the next two to three quarters. [Verdict — MODERATE-quality growth, improving in mix. The organic engine (myopia, daily-SiHy, fertility) is secular and margin-accretive, but the headline algorithm has decelerated to the low end of its 4–6% band and hinges on Asia-Pac stabilizing.]

6. Financial Quality

COO’s financial profile is the crux of the mispricing, because GAAP and economic reality diverge sharply.

Revenue and margins. Revenue compounded from $2,430.9M (FY2020) to $4,092.4M (FY2025) — a ~11% CAGR — but the trajectory decelerated: +20.2% (FY21, COVID rebound), +13.2% (FY22), +8.6% (FY23), +8.4% (FY24), +5.1% (FY25), with FY26 guided to +5–6%. Gross margin is consistently rich at 65–67% (FY25 65.5%; Q2 FY26 68.1%), reflecting the consumable lens model. Reported EBITDA margin sits ~26%. GAAP operating margin is ~16–18%, but this understates cash economics because ~$200M/yr of acquisition-intangible amortization runs through the P&L.

The amortization/EPS distortion (the single most important number to get right). GAAP diluted EPS was just $1.87 in FY2025, versus adjusted (non-GAAP) EPS of ~$3.90 and a FY26 guide of $4.58–$4.66. The gap is overwhelmingly amortization of intangibles (concentrated in CooperSurgical, $178.2M of the $199.2M group total) plus restructuring/impairment. This is why own-history valuation percentiles show a P/E percentile in the 82nd (rich) while price-to-sales sits in the ~5th and price-to-book in the ~7th (both cheapest-ever): the GAAP P/E is measuring a depressed denominator, not an expensive stock. When GAAP EPS is amortization-distorted, the honest read is price-to-book and price-to-sales — and those say cheap.

Returns on capital — genuinely low on GAAP, and honestly so. ROE was 5.0% and ROIC 4.2% in FY2025 (ROIC has run 3.8–4.6% for years). This is not an artifact — it is the real consequence of financing a roll-up: ~$3.85B of goodwill plus a matching intangibles stack sit in the invested-capital base against ~$680M of GAAP operating income. Adding back after-tax amortization lifts cash ROIC toward ~6–7%, still short of a ~8% WACC. Decomposed, the truth is stark and useful: CooperVision, with minimal goodwill attributable and $2.74B of sales at a 26.6% margin, earns a very high return on the tangible/operating capital it employs; CooperSurgical’s ~$3B of acquisition cost earns a low-single-digit GAAP return. The blended figure is a weighted average of a superb business and an expensively-bought one. (GOTCHA flagged: FY2021’s reported 62% ROE and $2.94B net income are an artifact of a one-time ~$2.45B deferred-tax benefit from an internal IP restructuring — strip it out; it is not repeatable and distorts every FY21 ratio.)

Cash flow and the inflection. Operating cash flow is strong and D&A-heavy (CFO/NI ~2.1x). But reported free cash flow has been suppressed by two forces: a heavy capex program (9–11% of sales — $310M→$421M/yr as COO built silicone-hydrogel lens capacity) and a persistent working-capital drag (−$285M in FY25; cash-conversion cycle ~212 days as lens inventory and receivables build with growth). FCF ran $176M (FY20), $524M (FY21), $450M (FY22), $215M (FY23), $288M (FY24), $434M (FY25). The bull case is a genuine inflection: capex is now normalizing, CFO grew to $796M in FY25, and management has raised FY26 FCF guidance to ~$650M (ex-litigation) and reaffirmed $2.2B cumulative FY26–28 (~$730M/yr average). Notably, part of the FY26 gross-margin guide-down to ~66% is a deliberate CooperVision inventory drawdown (enabled by a new AI inventory system) that pressures reported GM but releases cash — a quality-of-earnings nuance that favors FCF over accounting margin.

Balance sheet. Net debt ~$2.39B against ~$8.24B of book equity; net-debt/EBITDA ~2.25x; cash a thin $110M (COO sweeps cash against its revolver). Interest expense ~$85–100M/yr and falling as debt is repaid. This is a comfortably investment-grade balance sheet with ample capacity; leverage is not a thesis risk. Tangible book is modest given the goodwill, but the business is asset-rich in real manufacturing plant ($2.08B net PP&E).

[Verdict — economics clearly improve with scale in CooperVision (razor/razor-blade operating leverage), and cash generation is inflecting up as capex normalizes. The blemish is real and structural: blended GAAP/cash returns on the acquisition-loaded capital base sit below the cost of capital, and only a separation or many years of organic compounding fixes that. High-quality cash engine; mediocre return on the price paid to assemble the whole.]

7. Capital Allocation

The roll-up ledger — and its tombstone. CooperSurgical was assembled by acquisition: Paragard (~$1.1B, 2017, from Teva), Cook Medical reproductive assets (a 2018 tranche plus a further $300M deal in November 2023), Generate Life Sciences (~$1.6B, closed FY2022, ~6.4x TTM sales), obp Surgical ($100M, 2024), and myopia/fertility tuck-ins (SightGlass, Zymot). The residue sits on the FY2025 balance sheet as $3,853.4M of goodwill plus $1,586.3M of other intangibles — ~$5.44B combined, ~44% of assets and ~66% of book equity (tangible common equity is only ~$2.8B). Against GAAP ROIC of ~4–5% versus an ~8–9% WACC, that acquired capital has not earned its cost — Generate at ~6.4x sales is the emblematic overpay. This is the central capital-allocation critique, and it is precisely what the current strategic review exists to unwind (see the Changes section).

Capex and the FCF pivot. The other half of the capital story is more favorable: COO spent 9–11% of sales for years building CooperVision silicone-hydrogel capacity (FY25 capex $362M), suppressing reported FCF. That program is now normalizing, and FCF has ramped $215M (FY23) → $288M (FY24) → $434M (FY25), with FY26 guided to ~$650M and $2.2B reaffirmed cumulatively FY26–28. The capital cycle is turning from build-out to harvest.

Buybacks and debt. COO carries a $2.0B repurchase authorization with $966.4M remaining at October 2025. It repurchased 4.1M shares for $290.1M at an average ~$69.30 in FY25 — well-timed, ahead of the stock’s run to the $80s — with essentially none in FY24 (deleveraging + the Cook deal) and $108M in 1H-FY26. There is no meaningful dividend. Net debt is ~$2.3–2.4B (~2.25x EBITDA), cash a thin $110M. Management has signaled that if CooperSurgical is sold, the vast majority of proceeds would go to buybacks — a shareholder-friendly disposition of the separation.

Incentives (2026 DEF 14A). FY25 CEO pay (Al White) was $16.05M (~83% equity); CFO Andrews $4.34M. The annual bonus (85% financial) runs on constant-currency revenue, non-GAAP EPS, and free cash flow; FY25 company achievement was 101.1%, and — notably — the plan did penalize the weak unit (CooperSurgical division scored only 88.1%). The long-term plan received a genuine governance upgrade for FY2026: it moves from 100%-EPS-based PSUs to 50% time-vesting + 25% EPS-growth PSU + 25% relative-TSR PSU vs. the S&P Healthcare Equipment Index — the first market/relative metric. Ownership guidelines were tightened (CEO 5x→6x salary), and a clawback is in place. The red flag is the same one that afflicts ZBH: there is no ROIC or return-on-capital metric anywhere in the plan — the exact blind spot given the roll-up destroyed GAAP returns while adjusted EPS (which adds back the amortization) is rewarded.

Insider signal — a genuinely bullish tell. The Form 4 corpus shows a broad open-market purchase cluster (code P), not routine grants: buying in September 2025 (~$65–69) and again in December 2025 (~$80–84, just after the strategic-review/new-chair announcement), spanning the CEO, CFO, COO, both division presidents, and three independent directors — ~$2.5M aggregate, with CEO White personally buying 20,000 shares (~$1.49M). The only sizeable sells were programmatic exercise-and-sell into the ~$110 all-time highs in 2024. In short, insiders sold the top and bought the selloff — an unusually broad conviction signal that corroborates the contrarian framing.

[Verdict — mixed-to-below-average, improving. Management is a superb operator of CooperVision but a value-neutral-at-best allocator: the debt-funded fertility roll-up destroyed GAAP returns, and the comp plan still lacks a returns metric. Offsetting that: well-timed modest buybacks, a real LTI upgrade, a bullish insider-buying cluster, and — critically — a strategic review that would reverse the roll-up and return proceeds to holders. The allocation verdict is turning from negative toward constructive precisely because management is finally addressing the anchor.]

8. Changes and Headwinds — Last Two Years

The strategic review (the big one). In December 2025, alongside a board refresh — long-time Chairman Robert Weiss transitioning off — COO launched a strategic review, reportedly under pressure from activist JANA Partners. The working base case is a separation of CooperVision and CooperSurgical, with management citing “robust interest” in CooperSurgical (CSI) and signaling that the “vast majority of proceeds” from any sale would fund buybacks. Two caveats for discipline: (1) there is no definitive 8-K/transaction yet — this is management guidance sourced from the Q2 call and IR releases, not a signed deal; and (2) the PREM14A in the filing corpus is not a separation proxy — it is a preliminary version of the routine 2025 annual-meeting proxy (an officer-exculpation charter amendment), and should not be conflated with the review. This is the principal non-fundamental catalyst; it is also the structural cure for the sub-WACC blended ROIC.

The embryo culture-media recall — now quantified. The December-2023 recall of embryo culture media in the fertility business generated >140 lawsuits and >1,500 claimants; by Q2 FY26, settlements covered >95% of claimants, and COO booked a net P&L charge of $271.6M in Q2 FY26 ($324.1M accrued less $52.5M insurance, in SG&A), with the majority of the cash paid during FY2026. This is material and carries a critical valuation nuance: the ~$650M FY26 FCF guide is stated excluding litigation payouts — so reported FY26 FCF will be dented by this ~$272M (plus a final ~$50M Cook Medical installment). The “FCF inflection” is real on an underlying basis but is masked in FY26 by these one-time cash outflows — a point the bulls must acknowledge and the bears will press.

The FY26 guide cut. On June 4, 2026, COO cut its FY26 revenue guide to $4.28–4.32B (from higher) on Asia-Pac (Japan/China) softness, while maintaining adjusted EPS ($4.58–4.66) and raising the underlying FCF guide (~$650M). Sell-side responded with a wave of price-target cuts ($66–$92). A deliberate CooperVision inventory drawdown (via a new AI inventory system) is pressuring reported gross margin (~66% guide) but releasing cash.

Other changes. The 4-for-1 stock split took effect in 2024 (broadening the holder base); MyDay MiSight launched into Japan and Asia-Pac (2025–26); a new Asia-Pacific president was appointed (May 2026); and MiSight secured Japanese regulatory approval (2025). [Verdict — net thesis-strengthening. The strategic review + JANA involvement + insider buying materially raise the odds of a value-unlocking separation, and the recall liability is now largely resolved (a cleared overhang, at a known cost). The offset is the genuine Asia-Pac growth wobble and the FY26 reported-FCF dent from the settlement cash.]

9. Risk Analysis

The risk set is dominated by growth-durability and mispriced-returns concerns rather than solvency or catastrophic risk.

Catastrophic-loss / total-loss risk: very low. COO is a profitable, cash-generative, investment-grade business with irreplaceable manufacturing assets and durable end-market demand (vision correction, contraception, fertility). The realistic downside is multiple-and-growth disappointment (a drift back toward the high-$50s), not impairment of the enterprise.

10. Valuation Discussion (embedded expectations)

Where the multiple sits. At ~$74 (≈196M shares, ~$14.5B market cap, ~$16.8B EV), COO trades at ~15x EV/EBITDA, ~4.0x EV/sales, ~16x forward adjusted EPS ($4.62), and ~12x price-to-FCF on the FY26 ~$650M guide (falling toward ~10x on the $730M+ run-rate). Against its own history this is a decade trough: EV/EBITDA has averaged ~18–22x over ten years and peaked near 27x in 2021; EV/sales has ranged 5–7.5x; own-history valuation percentiles put price-to-sales in the ~5th percentile and price-to-book in the ~7th percentile of COO’s own multi-year range — i.e., cheaper than it has essentially ever been on the metrics that aren’t distorted by amortization. The GAAP P/E of ~40–60x is the one metric to ignore.

What the price embeds (reverse logic). At ~16x forward adjusted EPS with ~5% organic growth and a coming FCF ramp, the market is underwriting mid-single-digit growth fading toward maturity and no re-rating of the CooperVision franchise — pricing COO as a slow-growing, average-return medtech roll-up rather than as the owner of a wide-moat consumable oligopoly asset. For the current price to be too high, CooperVision organic growth must break structurally below ~3% (myopia-control share loss + secular contact-lens maturity) and the FCF inflection must fail. For it to be too low, either (a) organic growth simply holds in the mid-single digits and the FCF lands, re-rating the multiple back toward its own historical ~18x EV/EBITDA, or (b) the strategic review separates CooperSurgical and the market re-prices the CooperVision pure-play toward premium consumable-medtech multiples.

Scenario framing (illustrative, not targets):

• Bear: organic growth fades to ~2–3%, Asia-Pac stays weak, FCF ramp slips; the stock holds ~13–14x EV/EBITDA on stagnant EBITDA → high-$50s/low-$60s (roughly the May low).
• Base: ~5% organic growth, FY26 FCF ~$650M landing and rising, no corporate action; a modest re-rate toward ~16–17x EV/EBITDA → high-$70s/low-$80s.
• Bull: Asia-Pac stabilizes, MiSight re-accelerates, and CooperSurgical is separated; CooperVision re-rates toward ~20x+ EBITDA as a pure-play → ~$95–105 on the sum of the parts.

Sum-of-the-parts (rough, illustrative). Value CooperVision (~$2.74B sales, ~$750M EBITA, high growth) at a premium ~18–20x EBIT / ~5x sales ≈ $13.5–15B EV; CooperSurgical (~$1.35B sales, ~$222M EBITA, mid-single-digit growth) at ~12–14x EBITA / ~2–2.3x sales ≈ $2.7–3.1B EV; sum ~$16–18B, less ~$2.3B net debt → equity ~$13.7–15.7B ≈ ~$70–80/share. The current price is therefore roughly fair to modestly cheap on a conservative SOTP, with the upside optionality coming from a CooperVision re-rate that a clean separation would catalyze. No price target; no recommendation — the SOTP is an embedded-expectations tool, not a call.

11. Variant Perception

Consensus view. Sell-side is broadly constructive-but-chastened: a cluster of Buy/Outperform ratings with price targets cut to $85–$92 (Baird, Needham, Stifel, BNP) after the Q2 guide-down, and skeptics at Equal-Weight/Neutral with targets of $66–$71 (Wells Fargo, JP Morgan). The debate is entirely about growth durability — whether COO’s mid-single-digit organic algorithm is a temporary Asia-Pac air pocket or a structural maturation — not about business quality or solvency.

Strongest bull case. COO owns a genuine wide-moat consumable franchise (CooperVision) inside a four-firm oligopoly with a secular myopia tailwind, priced at a decade-low multiple because ~$200M/yr of non-cash amortization disguises its real ~$4.62 cash EPS and a FCF inflection is about to flood the P&L with cash ($2.2B over FY26–28). A strategic review — pushed by activist JANA Partners, with a board refresh and management’s own base case pointing to separation — offers a catalyzed path to spin/sell the low-return women’s-health roll-up, return the proceeds to buybacks, and re-rate the lens business toward the 20x+ multiple premium consumable medtech commands. Broad insider buying into the selloff (CEO included) says management agrees the stock is cheap. You are buying quality at a value price with an activist-backed catalyst.

Strongest bear case. The reported numbers are honest: blended ROIC is ~4–5%, below the cost of capital, because management overpaid to assemble CooperSurgical and now adds back the amortization while being paid on adjusted metrics. Organic growth has decelerated three years running toward the low end of its band, the largest growth vector (myopia control) faces spectacle-lens substitution, and Asia-Pac — the fastest-growing lens region — is deteriorating. The “cheap” multiple is cheap for a reason: a maturing, average-return roll-up whose FCF “inflection” is partly a one-time inventory drawdown.

The 3–5 assumptions that matter most: (1) Is CooperVision’s organic growth durably mid-single-digit or structurally fading? (2) Does the FY26–28 FCF ramp actually land (capex normalization + WC discipline), or does working capital keep eating it? (3) Will the strategic review produce a value-unlocking CooperSurgical separation, or nothing? (4) Is MiSight’s myopia lead durable against spectacle lenses, or eroding? (5) Does Asia-Pac stabilize within a few quarters or signal broader demand weakness?

Factor-positioning read (from the tape). A quantitative factor model reads COO as a low-beta (0.72), negative-momentum, low-vol defensive medtech with negative alpha and five years of negative Sharpe — an abandoned, de-rated name, not a crowded trade. The recent m3 bounce (~+5.7% actual quarter off the May low, showing as ~+25% annualized) is the first sign of stabilization. This is empirical support for the contrarian framing: consensus is offsides bearish on a quality asset, the mirror image of a momentum blow-off. It is evidence of where sentiment sits, not a price call.

12. Fact vs. Interpretation

13. Open Questions

1. The embryo culture-media recall charge is now known (~$271.6M net, majority of cash paid in FY26); the residual questions are the size of any long-tail claims beyond the >95% settled, and exactly how much the ~$272M + ~$50M Cook installment depress reported FY26 FCF versus the ex-litigation ~$650M guide.
2. What form and timing will the strategic review take — full CooperSurgical spin/sale, partial, or “no action”? What multiple could CooperSurgical fetch?
3. How much of the FY26 FCF raise is durable cash generation vs a one-time CooperVision inventory drawdown that does not repeat?
4. Is the Asia-Pac (Japan/China) softness cyclical consumer weakness or a structural share/channel problem (e.g., e-commerce shift where COO is weaker)?
5. How durable is MiSight’s myopia-control moat as spectacle-lens rivals (HOYA, EssilorLuxottica) scale — does contact-lens myopia control keep share, or cede it?
6. On a stand-alone basis, what are the true fully-burdened operating margins and FCF of each segment once shared/back-office costs and the transition-services overhang are allocated?

14. What Must Be True

Bull case — what must be true, and its falsification test. CooperVision must sustain mid-single-digit-or-better organic growth (myopia control + silicone-hydrogel mix + share gains) with Asia-Pac stabilizing; the FY26–28 FCF ramp must land as capex normalizes; and the strategic review must credibly move toward separating/valuing CooperSurgical. Falsification: two-plus consecutive quarters of CooperVision organic growth below ~3% and/or FY26 FCF tracking materially below the ~$650M guide would break the “quality-compounder-at-a-price with a catalyst” thesis.

Bear case — what must be true, and its falsification test. Organic growth must be structurally maturing (not a temporary air pocket), MiSight must be losing the myopia battle to spectacles, and the roll-up’s sub-WACC returns must persist with no value-unlocking action. Falsification: Asia-Pac returning to growth and a formal CooperSurgical separation announcement and the FCF inflection landing would refute the “maturing average-return roll-up” case and force a re-rating toward the sum of the parts.

APPENDIX A — Standard Diligence Questionnaire

The Cooper Companies, Inc. (NASDAQ: COO) — supplemental diligence questionnaire. Fact / Interpretation / Assumption labeled where it matters. Not counted toward the memo length standard.

General

What thoughtful questions have other investors asked about this company? The dominant investor debate is growth durability vs. a value multiple: is COO’s deceleration to ~5% organic a temporary Asia-Pac air pocket or structural maturation of the contact-lens/fertility franchises? Secondary questions: (1) Why is GAAP ROIC only ~4–5% and does that mean the moat is fake? (Answer: no — it is roll-up goodwill masking a two-speed business.) (2) Is the FY26–28 $2.2B FCF real or engineered by a one-time inventory drawdown? (3) Will the strategic review actually separate CooperSurgical, and what is it worth? (4) Can MiSight hold its myopia lead against cheaper spectacle lenses? (5) How large is the fertility-recall litigation tail?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither extreme. Revenue growth has decelerated (11% CAGR → ~5%), so the growth rate is at a cyclical low; margins are mid-range; FCF is inflecting up from a capex-suppressed trough. [Interpretation] Driven by external environment or internal action? Both — the Asia-Pac (Japan/China) consumer softness is external; the FCF inflection and margin discipline are internal. How stable are revenues? Very — >90% recurring consumable (lenses re-ordered continuously; fertility consumables; Paragard). Outlook for products/services? Structurally growing end-markets (vision correction, myopia epidemic, IVF). How big will the market be? Soft contact lenses ~$9.8B growing 6–8%; myopia-control lenses ~$1.6B→$4.0B (~15.6% CAGR); IVF ~$28B→$46B (~5.7%). Global, majority international.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable-to-consolidating — a disciplined 4-firm lens oligopoly; fertility consolidating (Astorg/Hamilton Thorne). [Fact/Interpretation] How profitable is the business (ROIC, ROE)? GAAP ROE 5.0%, ROIC 4.2% (FY25) — optically low due to $3.85B roll-up goodwill; CooperVision earns a very high return on its real operating capital (26.6% segment operating margin). How profitable is the industry? Highly, for the lens majors (65%+ gross margins); barriers to entry are high (SiHy capex, SKU breadth, regulatory). Can the business be easily understood? Yes — a razor/razor-blade consumable plus a fertility/women’s-health portfolio. Undermined by foreign low-cost labor? No — regulated Class II/III medical devices with high manufacturing precision and clinical/regulatory barriers. Do brands matter? Moderately — the fitter (ECP) relationship matters more than consumer brand; MyDay/Biofinity/MiSight carry professional-channel equity. Nature of competition? Oligopolistic mix-up and share-defense, not price war. Switching costs? Real via the fit relationship (patients captive to the fitter’s chosen brand) and via validated embryology-lab protocols in fertility.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The CooperVision franchise value / brand / ECP relationships are not capitalized; conversely, ~$3.85B goodwill + intangibles are on the sheet from acquisitions. Off-balance-sheet liabilities? Standard operating leases; the fertility-recall settlement liability (largely settled, excluded from the $2.2B FCF figure). [Open Question on magnitude] How conservative is the accounting? Reasonable; the large gap between GAAP EPS ($1.87) and adjusted EPS (~$4.62) is transparent amortization, not aggressive capitalization — though investors should verify adjusted add-backs are non-cash. How CapEx-hungry? Historically yes (9–11% of sales building lens capacity); now normalizing — the core of the FCF-inflection thesis.

Capital Allocation & Management

How much FCF, and how used? FCF inflecting to ~$650M (FY26) → ~$730M+ run-rate; historically directed to debt paydown and modest buybacks, minimal dividend. Philosophy? Reinvest for organic growth + capacity, deleverage, opportunistic buyback; the M&A engine (CooperSurgical roll-up) has paused, and a divestiture is now under review. Significant acquisitions recently? The last major was Generate Life Sciences (~$1.6B, 2022); the roll-up (Paragard ~$1.1B 2017, Cook reproductive 2018) built CooperSurgical. (see the Capital Allocation section) Buying back shares? Modestly (~$290M FY25, ~$13M Q2 FY26) — net share count slowly declining. Issuing shares to insiders? SBC ~$70M/yr, ordinary. Compensation/motivation? Verify the incentive metrics (revenue/EPS/TSR) and whether any ROIC gate exists. Long-tenured CEO (Al White) and CFO (Brian Andrews) with a solid execution record.

Valuation & Market Data

ADR / MLP / K-1? No — ordinary US common stock, NASDAQ: COO. Dividend policy? Nominal (historically a token annual dividend); this is a capital-appreciation/deleveraging story, not an income name. How profitable? Very, on a cash basis; low on GAAP due to amortization. Net income diverging from cash flow? Yes — CFO/NI ~2.1x because D&A (esp. amortization) is a large non-cash charge; cash generation materially exceeds GAAP net income. This favors the stock (GAAP understates economics).

Risks & Downside

What would cause the stock to decline? CooperVision organic growth breaking below ~3%; Asia-Pac deterioration spreading; MiSight ceding myopia share to spectacles; the FCF ramp slipping; the strategic review producing nothing; a large litigation charge. Catastrophic-loss risk? Very low — profitable, cash-generative, investment-grade, irreplaceable manufacturing base, durable demand. Total-loss risk? Negligible.

Recent News & Events

Has the environment changed recently? Yes — Q2 FY26 (June 4) cut the FY26 revenue guide on Asia-Pac softness while raising the FCF guide; a strategic review (potential CooperSurgical separation) is underway; the Dec-2023 embryo culture-media recall litigation is largely settled; sell-side cut price targets to $66–$92. Significant acquisitions? None recent — the focus has shifted to a possible divestiture. Accounting changes? None material; a new AI-driven CooperVision inventory system is deliberately drawing down stock (pressuring reported GM, releasing cash). Recent changes — new markets, facilities, management? MyDay MiSight launched into Japan/Asia-Pac; a new Asia-Pacific president appointed (May 2026); the 4-for-1 stock split took effect in 2024.

APPENDIX B — Source Appendix

The Cooper Companies, Inc. (NASDAQ: COO). Report date 2026-07-04. Primary sources first. Third-party aggregated/estimated data is labeled and reconciled to filings; management commentary is treated as hypothesis validated against filings and external evidence.

Primary — SEC filings (SEC EDGAR, CIK 0000711404)

• FY2025 Form 10-K (filed 2025-12-05, period ending 2025-10-31) — segment net sales, margins, goodwill/intangibles, capex, debt. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000711404&type=10-K
• Form 10-Q, Q2 FY2026 (filed 2026-06-05, period ending 2026-04-30) — Q2 results, embryo-recall charge detail, Cook installment.
• 8-K (2026-06-04) — Q2 FY26 earnings release, FY26 guidance update, Item 8.01 embryo culture-media recall charge ($271.6M net). Press release: https://www.sec.gov/Archives/edgar/data/0000711404/000162828026040823/cooperq22026pressrelease.htm
• DEF 14A (2026-02-24) — executive compensation, incentive-plan metrics (constant-currency revenue / non-GAAP EPS / FCF; FY26 relative-TSR PSU addition), ownership guidelines.
• Form 4 corpus (151 filings) — insider transactions; open-market purchase cluster Sep-2025 (~$65–69) and Dec-2025 (~$80–84), CEO White +20,000 sh (~$1.49M); 2024 exercise-and-sell into ~$110 highs. via SEC EDGAR (CIK 0000711404).
• Prior 10-Ks (FY2021–FY2024) — multi-year revenue/segment/capex trend.
• Note: the PREM14A (2025-02-07) is a preliminary annual-meeting proxy (officer-exculpation charter amendment), not a separation/merger proxy.

Primary — company IR / press

• CooperCompanies — new Board Chair & strategic review (Dec 2025): https://investor.coopercos.com/news-releases/news-release-details/coopercompanies-announces-new-chair-board-and-strategic-review
• CooperCompanies — Generate Life Sciences acquisition ($1.6B, 2021-11-10): https://www.globenewswire.com/news-release/2021/11/10/2332070/2200/en/CooperCompanies-to-Acquire-Generate-Life-Sciences-for-1-6-Billion.html
• Q2 FY2026 earnings call transcript (2026-06-04) — CEO Al White / CFO Brian Andrews; segment growth, MiSight +24%, Asia-Pac softness, FCF guidance, strategic-review and separation Q&A, “CVI stand-alone” commentary.

Quantitative aggregators (labeled; reconciled to filings)

• Aggregated fundamentals — income statement, balance sheet, cash flow, profitability ratios (ROE/ROIC), enterprise value, valuation multiples (FY2016–FY2025), reconciled to SEC filings (EDGAR primary).
• News flow (Q2-FY26 print, sell-side price-target cuts) and own-history valuation percentiles (P/S ~5th, P/B ~7th; GAAP P/E ~82nd percentile flagged as amortization-distorted and disregarded).
• Factor-model data — factor loadings (beta 0.72, negative momentum/alpha), leaderboard (5-yr return −5.6%/yr, m3 bounce), stock-info (52wk range, relative strength). Third-party statistical estimates.
• Split-adjusted 5-yr price/OHLCV data for the price-action event map (5-yr high ~$114 Sep-2021, low $58.98 May-2026, $74.20 Jul-2026).

Industry / third-party

• Soft contact-lens market size/growth and 4-player share (J&J / Alcon / CooperVision / B+L); silicone-hydrogel and daily-disposable mix — industry market-research syntheses and company filings.
• Myopia-management lens market (~$1.6B→$4.0B, ~15.6% CAGR); MiSight FDA approval (2019) and Japan approval (2025); competitors HOYA MiYOSMART, EssilorLuxottica Stellest, ZEISS.
• IVF/ART market (~$28B→$46B, ~5.7% CAGR); California SB 729 infertility-coverage mandate (eff. Jan 2026); competitors Vitrolife, Thermo Fisher/Irvine, Cook Medical, Hamilton Thorne (Astorg).
• Paragard — sole US non-hormonal copper IUD (FDA 1984; acquired from Teva 2017 ~$1.1B).

Analytical frameworks

• Greenwald & Kahn (Competition Demystified: economies of scale + customer captivity; barriers-to-entry/ROIC tests) and Marathon (Capital Returns: capital-cycle, asset-growth anomaly) applied to the moat, industry, and capital-allocation analysis.